Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 14, 2024Breast Cancer Research and TreatmentOpen Access

The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

CJChristian JackischLALouiza AnastasiadouSASebastian Aulmann

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jackisch et al. (2024) studied this question.

synapsesocial.com/papers/68e64b29b6db6435875dbbe4https://doi.org/10.1007/s10549-024-07390-y
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PS3-09-01: Use of the OncotypeDX Recurrence Score® (RS) as a continuous prognostic biomarker in hormone receptor (HR) positive HER2neu negative early breast cancer with intermediate risk of recurrence may asses risk of recurrence or death more appropriately2026
  2. 2Impact of the 21-Gene Oncotype DX Recurrence Score on Adjuvant Chemotherapy Decision-Making in Invasive Ductal Carcinoma: A Real-World Analysis From a Single Japanese Institution2026
  3. 3Abstract PO3-15-04: Oncotype DX Recurrence Score as an Informative Tool to Optimize Neoadjuvant Therapy in HR-positive, HER2-negative Breast Cancers2024 · 1 citations
  4. 4Abstract PS3-08-11: Correlation between clinical-pathological features and recurrence score from a multigene predictive assay in hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer: a real-world, retrospective, monocentric analysis of over 700 patients2026
  5. 5Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland2024 · 1 citations